CSIMarket
 


Regeneron Pharmaceuticals Inc   (REGN)
Other Ticker:  
 

Regeneron Pharmaceuticals Inc 's Quick Ratio

REGN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regeneron Pharmaceuticals Inc 's Cash & cash equivalent grew by 9.39 % in the IV Quarter 2023 sequentially, while Current Liabilities decreased, this led to improvement in Regeneron Pharmaceuticals Inc 's Quick Ratio to 3.66 a new company high.

Within Major Pharmaceutical Preparations industry 43 other companies have achieved higher Quick Ratio than Regeneron Pharmaceuticals Inc in forth quarter 2023. While Quick Ratio total ranking has improved so far during the IV Quarter 2023 to 246, from total ranking in the third quarter 2023 at 345.

Explain Quick Ratio?
How much Cash & cash equivalents REGN´s has?
What are REGN´s Current Liabilities?


REGN Quick Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Change 11.31 % 36.42 % 10.36 % 6.26 % -3.88 %
Y / Y Cash & cash equivalent Change 40.07 % 41.19 % 17.99 % 27.08 % 35.96 %
Quick Ratio MRQ 3.66 3.12 3.28 3.35 2.91
REGN's Total Ranking # 246 # 345 # 335 # 433 # 277
Seq. Current Liabilities Change -6.81 % 16.82 % 1.85 % 0.39 % 14.21 %
Seq. Cash & cash equivalent Change 9.39 % 11.04 % -0.36 % 15.72 % 10.26 %



Quick Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 44
Healthcare Sector # 80
Overall Market # 246


Quick Ratio Statistics
High Average Low
3.66 1.92 0.84
(Dec 31 2023)   (Dec 31 2016)




Financial Statements
Regeneron Pharmaceuticals Inc 's Current Liabilities $ 2,965 Millions Visit REGN's Balance sheet
Regeneron Pharmaceuticals Inc 's Cash & cash equivalent $ 10,845 Millions Visit REGN's Balance sheet
Source of REGN's Sales Visit REGN's Sales by Geography


Cumulative Regeneron Pharmaceuticals Inc 's Quick Ratio

REGN's Quick Ratio for the trailling 12 Months

REGN Quick Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities TTM Growth 11.31 % 36.42 % 10.36 % 6.26 % -3.88 %
Y / Y Cash & cash equivalent TTM Growth 40.07 % 41.19 % 17.99 % 27.08 % 35.96 %
Quick Ratio TTM 3.35 3.16 3.14 3.09 2.94
Total Ranking TTM # 283 # 234 # 1459 # 1805 # 409
Seq. Current Liabilities TTM Growth -6.81 % 16.82 % 1.85 % 0.39 % 14.21 %
Seq. Cash & cash equivalent TTM Growth 9.39 % 11.04 % -0.36 % 15.72 % 10.26 %


On the trailing twelve months basis REGN Cash & cash equivalent soared by 40.07 % in IV Quarter 2023 year on year, faster than Current Liabilities, this led to increase in in Regeneron Pharmaceuticals Inc 's Quick Ratio to 3.35, above REGN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 82 other companies have achieved higher Quick Ratio than Regeneron Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2023 from 234 to 283.

Explain Quick Ratio?
How much Cash & cash equivalents REGN´s has?
What are REGN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 83
Healthcare Sector # 156
Within the Market # 283


trailing twelve months Quick Ratio Statistics
High Average Low
2.92 1.63 1.06
(Dec 31 2023)   (Sep 30 2017)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Cryoport inc   10.05 $ 458.435  Millions$ 45.610  Millions
Aprea Therapeutics Inc   9.82 $ 21.607  Millions$ 2.199  Millions
Virios Therapeutics Inc   9.25 $ 3.317  Millions$ 0.359  Millions
Milestone Pharmaceuticals inc   9.13 $ 66.003  Millions$ 7.226  Millions
Summit Therapeutics Inc   9.13 $ 186.242  Millions$ 20.405  Millions
Neurogene Inc   8.58 $ 197.157  Millions$ 22.973  Millions
Lipella Pharmaceuticals Inc   8.55 $ 3.294  Millions$ 0.385  Millions
Lipocine Inc   8.43 $ 22.036  Millions$ 2.614  Millions
Sol gel Technologies Ltd   8.40 $ 37.996  Millions$ 4.522  Millions
Oncolytics Biotech Inc   8.24 $ 26.743  Millions$ 3.246  Millions
Xoma Corporation  7.86 $ 153.290  Millions$ 19.499  Millions
Alpine Immune Sciences Inc   7.80 $ 327.412  Millions$ 41.980  Millions
Abcellera Biologics Inc   7.60 $ 760.585  Millions$ 100.055  Millions
Bicycle Therapeutics Plc  7.57 $ 526.423  Millions$ 69.537  Millions
Inmed Pharmaceuticals Inc   7.28 $ 9.579  Millions$ 1.316  Millions
Ngm Biopharmaceuticals Inc   7.18 $ 144.185  Millions$ 20.081  Millions
Kronos Bio Inc   7.01 $ 172.997  Millions$ 24.695  Millions
Zentalis Pharmaceuticals Inc   6.96 $ 482.919  Millions$ 69.367  Millions
Werewolf Therapeutics Inc   6.93 $ 134.343  Millions$ 19.378  Millions
Zymeworks Inc   6.71 $ 374.327  Millions$ 55.763  Millions
Generation Bio Co   6.62 $ 264.364  Millions$ 39.914  Millions
Salarius Pharmaceuticals inc   6.61 $ 5.900  Millions$ 0.892  Millions
Anebulo Pharmaceuticals Inc   6.56 $ 6.645  Millions$ 1.014  Millions
Royalty Pharma Plc  6.33 $ 495.310  Millions$ 78.222  Millions
Capricor Therapeutics inc   6.32 $ 39.488  Millions$ 6.250  Millions
Glycomimetics Inc   6.11 $ 41.793  Millions$ 6.835  Millions
Tharimmune Inc   6.02 $ 10.935  Millions$ 1.815  Millions
Artelo Biosciences Inc   5.90 $ 7.611  Millions$ 1.291  Millions
Ac Immune Sa  5.78 $ 78.494  Millions$ 13.576  Millions
Gossamer Bio Inc   5.74 $ 296.425  Millions$ 51.598  Millions

Date modified: 2024-02-05T17:20:45+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com